<?xml version="1.0" encoding="UTF-8"?>
<p id="Par27">Crystals of myristoylated cabotegravir prodrug that were formulated into NPs facilitated avid monocyte-macrophage entry, retention, and reticuloendothelial system depot formulation, showed sustained protection against HIV-1 challenge, and a single 45 mg/kg intramuscular injection of these NPs at a dose of 45 mg/kg to BALB/cJ mice resulted in fourfold higher pharmacokinetic profiles compared to long-acting parenteral cabotegravir, and similar results were obtained also with rhesus macaques (
 <italic>Macaca mulatta</italic>); improved viral restriction in human adult lymphocyte-reconstituted NOD/SCID/IL2Rγc
 <sup>−</sup>
 <sup>/</sup>
 <sup>−</sup> mice by this nanoformulations was observed as well (Zhou et al. 
 <xref ref-type="bibr" rid="CR247">2018</xref>).
</p>
